The effect of resistant hypertension on in-hospital mortality in patients hospitalized with COVID-19
| Autor: | Abdurrahman Akyüz, Ümit İnci, Neşe Kanbal Çap, İlyas Kaya, Metin Okşul, Burhan Aslan, Ercan Taştan, Erkan Baysal, Önder Bilge, Ferhat Işık, Murat Çap, Ali Karagöz |
|---|---|
| Přispěvatelé: | Dicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalı, Çap, Neşe Kanbal |
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Hipertansiyon business.industry Mortality rate Comment COVID-19 Retrospective cohort study Odds ratio Procalcitonin Confidence interval Hospitalization Risk factors Concomitant Internal medicine Hypertension Internal Medicine medicine Population study Humans Female Hospital Mortality Adverse effect business Retrospective Studies |
| Zdroj: | Journal of Human Hypertension |
| ISSN: | 1476-5527 |
| Popis: | WOS:000681541900001 PMID34354253 Hypertension is a major concomitant disease in hospitalized patients with COVID-19 (Coronavirus disease 2019) infection. The adverse effect of hypertension on prognosis in COVID-19 is known. Nevertheless, it is not known how COVID-19 progresses in resistant hypertensive patients. In this study, we aimed to examine the effect of resistant hypertension (ResHT) on in-hospital mortality in patients hospitalized with COVID-19. In our single-center retrospective study, included 1897 COVID-19 patients. The patients were divided into three groups according to the non-hypertensive (n = 1211), regulated HT (RegHT) (n = 574), and ResHT (n = 112). These three groups were compared according to demographic features, clinical signs, laboratory findings, and follow-up times. The median age of the study population was 62 (50–72 IQR) and 1000 (52.7%) of patients were male. The total mortality of the study population was 18.7% (n = 356). Mortality rates were similar in the hypertensive patient group (27.5% for the RegHT and 32.1% for ResHT, p = 0.321). In a multivariable analysis, ResHT was independently associated with a significantly increased risk of inhospital mortality of COVID-19, while no significant increased risk was observed with RegHT [respectively, Odds Ratio (OR) = 2.013, Confidence Interval (CI) 1.085–3.734, p = 0.026 and OR = 1.194, CI 0.795–1.794, p = 0.394]. Also, age, male gender, chronic renal failure, lymphocyte, procalcitonin, creatinine, and admission SpO2 levels were determined as independent predictors of in-hospital mortality. In our study, it was found that ResHT was an independent predictor of mortality in patients hospitalized with COVID-19; however, this situation was not found in RegHT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink